Clinical outcomes of umbilical cord blood transplantation for AML patients in the era of FLT3 inhibitors
Not Applicable
Recruiting
- Conditions
- Acute myeolid leukemiaacute myeloid leukemia, FLT3-mutation, gilteritinibD015470
- Registration Number
- JPRN-jRCT1031230158
- Lead Sponsor
- chida Naoyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Adult AML patients who received UCBT in Toranomon Hospital between January 1st, 2019 and December 31st, 2023.
Exclusion Criteria
Patients who declared not to participate the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method